eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Spectrum Thea Pharmaceuticals Limited

Telephone: (0)845 5211 290
Fax: +44(0)1625 619 959
Medical Information Direct Line: +44 (0)79 074 344 03
Medical Information e-mail: medical.enquiries@spectrum-thea.co.uk
Customer Care direct line: 0845 521 1290
Medical Information Fax: +44(0)1625 619 959

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 19/07/2011
SPC Liquivisc


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

LlQUlVISC 2.5 mg/g, eye gel


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Carbomer 974P 2.5 mg/g.

Excipient: benzalkonium chloride (0.06 mg/g).

For a full list of excipients, see section 6.1.


Go to top of the page
3. PHARMACEUTICAL FORM

Eye gel

Slightly yellow and opalescent gel.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Symptomatic treatment of dry eye syndrome.


Go to top of the page
4.2 Posology and method of administration

Ocular use.

Adults (including the elderly):

Instil one drop of the gel into the inferior conjunctival cul-de-sac 1 to 4 times daily according to the degree of ocular trouble.

Children:

No specific studies with LIQUIVISC 2.5 mg/g, eye gel have been performed in children. It is recommended that LlQUlVISC 2.5 mg/g, eye gel should not be used in children until further data becomes available.

After instillation, the bottle should be stored vertically with the dropper downwards to facilitate the formation of drops when next used.

Do not touch the eye with the dropper tip. Replace the cap after use.


Go to top of the page
4.3 Contraindications

Hypersensitivity to any of the components of the product.


Go to top of the page
4.4 Special warnings and precautions for use

Benzalkonium chloride is commonly used as a preservative in ophthalmic products and has been reported rarely to cause punctate keratopathy and/or ulcerative keratopathy.

Contact lenses :

Benzalkonium chloride may be absorbed by and discolour contact lenses and therefore the patients should be instructed to wait until 30 minutes after instillation of LIQUIVISC 2.5 mg/g, eye gel before inserting contact lenses.

If symptoms continue or worsen, the patient should be reviewed by a physician.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

In case of concomitant use with other eye drops, wait for 15 minutes between instillations.

LIQUIVISC 2.5 mg/g, eye gel should be the last medication instilled.


Go to top of the page
4.6 Pregnancy and lactation

LIQUIVISC 2.5 mg/g, eye gel was not studied in pregnant and breast-feeding women.

Caution should be exercised when prescribing to pregnant or breast-feeding women.


Go to top of the page
4.7 Effects on ability to drive and use machines

Vision may be blurred for a few minutes after the instillation.

If affected, the patient should be advised not to drive or operate hazardous machinery until normal vision is restored.


Go to top of the page
4.8 Undesirable effects

As for other eye drops, possibility of mild transient stinging or burning upon instillation.

Blurred vision may occur briefly after instillation until the gel is evenly distributed over the eye surface.


Go to top of the page
4.9 Overdose

Any ocular overdose or oral intake that could occur is of no clinical relevance.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

TEAR SUBSTITUTE

(S : Sensory organ (eye))

- Fluid eye gel based on a high molecular weight hydrophilic polymer (carbomer 974P).

- Due to its physical properties, this gel forms a transparent lubricating and wetting film on the surface of the eye, temporarily compensating for tear insufficiency.

- Its pH (7.3) and osmolality are similar to those of the normal tear film.

- Its viscosity (700 mPas) is greater than that of artificial tears, allowing less frequent administration.


Go to top of the page
5.2 Pharmacokinetic properties

Because of the relatively large size of the carbomer molecule, penetration through the cornea is unlikely.

The persistence time of the gel on the eye surface is about 30 minutes.


Go to top of the page
5.3 Preclinical safety data

Data from subacute toxicity and local tolerance studies do not show any relevant findings.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Benzalkonium chloride

Sorbitol

Lysine monohydrate

Sodium acetate

Polyvinyl alcohol

Water for injections


Go to top of the page
6.2 Incompatibilities

Not applicable.


Go to top of the page
6.3 Shelf life

Shelf life prior to opening:

30 months.

In-use shelf life:

4 weeks.


Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C. Store container in the outer carton, in order to protect from light.


Go to top of the page
6.5 Nature and contents of container

10 g in 10 m1 bottle (PE) with dropper (PE).


Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Laboratoires Thea

12 rue Louis Blériot

Z.I.du Brézet

63017 Clermont-Ferrand Cedex 2

France


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 20162/0009


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

10/06/2008


Go to top of the page
10. DATE OF REVISION OF THE TEXT

10/06/2008



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/24741/SPC/


Active Ingredients/Generics

 
   carbomer